Drugs / VX-407
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07074327 | Jul 2025 → Feb 2026 | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT07022119 | Jun 2025 → Feb 2026 | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06345755 | Apr 2024 → Jan 2025 | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07161037 | Nov 2025 → Jul 2027 expected | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-21 | Vertex Pharmaceuticals Incorporated | Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06345755 ↗ |
| Action | Restore | “the polycystin-1 correcting agent VX-407.” PMID 41348481 ↗ Dec 2025 |
| Route | Oral | “Solution or Suspension for oral administration.” NCT06345755 ↗ |